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Introduction
Inflammatory dilated cardiomyopathy is a common cause of heart failure in young patients and often results from myocarditis in predisposed individuals [1] . CD4 + T-cell-mediated experimental autoimmune myocarditis (EAM) is a model for inflammatory heart disease and is induced in mice either by immunization with α-myosin heavy chain (α-MyHC) derived peptides emulsified in CFA [2] [3] [4] or by vaccination with α-MyHC-loaded activated dendritic cells (DCs) [5] . Typically, both Th1 and Th17 cells are induced during the course of EAM. It is assumed that both of these subsets mediate myocarditis as mice deficient in either interleukin 17 (IL-17) or interferon γ (IFN-γ) develop cardiac pathology [6, 7] . Remarkably, heart-specific autoimmune inflammation has been shown to be a consequence of impaired central tolerance induction to α-MyHC during T-cell development in mice and in humans [8] . CD4 + T-cell-orchestrated immune responses are driven by MHC class II (MHCII) mediated antigen presentation. MHCII is primarily expressed on professional APCs. Cardiac APCs were suggested to present cardiac myosin before the onset of cardiac pathology [9] , and DCs, the major APC subset able to initiate primary immune responses, were shown to be critical for disease induction [5, 10] . However, MHCII molecules are also upregulated on nonhematopoietic cells under inflammatory conditions [11, 12] . In fact, MHCII expression can be observed on cardiac nonhematopoietic cells during myocarditis in both humans and rodents [13] [14] [15] . Induction of MHC class II molecules depends critically on IFN-γ, which is dominantly expressed during myocarditis [16] [17] [18] . Interestingly, IFN-γ plays a dual role in myocarditis. On the one hand, IFN-γ exerts a protective role by limiting the expansion of autoreactive heart-specific CD4 + T cells. On the other hand, several observations point to a-not yet understood-disease promoting role for IFN-γ during myocarditis induction [19] [20] [21] [22] [23] .
The class II transactivator (CIITA) directs the cell type specific expression of the MHCII antigen presentation machinery. The expression of CIITA is tightly regulated by three independent promoters, pI, pIII, and pIV, which are active in a cell type specific manner [12] . pI activity is mainly restricted to myeloid cells and pIII is active in lymphoid cells. Here, we take advantage of the fact that in pIV−/− mice IFN-γ-inducible MHCII expression is specifically abrogated in nonhematopoietic cells [24, 25] . It was previously shown that positive selection of CD4 + T cells does not occur in pIV−/− mice due to the absence of MHCII on cortical thymic epithelial cells [24] . However, transgenic (Tg) expression of CIITA controlled by the keratin-14 (K14) promoter reestablishes thymic CD4 + T-cell selection: The resulting pIV−/− K14 CIITA Tg mice exhibit normal and functional CD4 + T cells and MHCII expression on professional APCs (which are directed by pI and pIII) but selectively miss inducible nonhematopoietic MHCII expression [12, [24] [25] [26] .
Here, we investigated the role of nonhematopoietic MHCII expression in myocarditis using the EAM model. We found that lack of inducible nonhematopoietic MHCII expression in pIV−/− K14 CIITA Tg mice protected from EAM. In contrast, cardiac pathology was inducible in WT and heterozygous control mice, and correlated with elevated cardiac and endothelial MHCII expression. EAM in these mice was characterized by elevated levels of infiltrating CD4 + T cells and increased expression of IFN-γ, which is the major driver of nonhematopoietic MHCII expression. Accordingly, neutralization of IFN-γ in WT mice 9 days after immunization resulted in reduced cardiac MHCII expression and pathology. Taken together, these findings prove for the first time a critical role of nonhematopoietic MHCII expression in the development of myocarditis.
Results

Absence of nonhematopoietic MHCII expression prevents EAM
pIV−/− K14 CIITA Tg mice are devoid of nonhematopoietic MHCII expression but possess normal CD4 + T-cell populations in the thymus and the periphery that own WT T-cell receptor V β chain repertoires [26] . Accordingly, these mice also show a normal distribution of thymic and peripheral CD4 + naïve, effector, memory, and FoxP3 + T-cell subsets [25] . Fig. 1 ). Our data indicate that the phenotype and functions of CD4 + T cells are normal in pIV−/− K14 CIITA Tg mice. We aimed to examine the role of nonhematopoietic MHCII expression in EAM. To this end, female age-matched, microbiomeadapted, pIV−/− K14 CIITA Tg mice, and heterozygous and WT controls were injected with α-MyHC-derived peptide and CFA. While heterozygous and WT control mice developed severe cardiac inflammation, inflammatory infiltrates were absent in hearts of pIV−/− K14 CIITA Tg mice ( Fig. 1A and B) . Moreover, cardiac troponin T (cTnT), a surrogate marker for cardiac damage in peripheral blood, was elevated in pIV+/− K14 CIITA Tg and WT mice, but not in pIV−/− K14 CIITA Tg mice (Fig. 1C) . Finally, adoptive transfer of CD4 + T cells from previously immunized pIV−/− K14 CIITA Tg mice was able to induce EAM in sublethally irradiated WT mice to a similar extent as their heterozygous counterparts (Fig. 1D ), indicating that heart-specific, pathogenic T cells expand in pIV−/− K14 CIITA Tg mice. Taken together, absence of inducible nonhematopoietic MHCII expression protects from autoimmune myocarditis even in the presence of heart-specific autoreactive CD4 + T-cell expansion.
Endothelial MHCII expression is induced during EAM
Next, we examined whether MHCII molecules are expressed in inflamed hearts of heterozygous and WT mice. MHCII expression was strongly upregulated in large areas restricted to inflammatory cardiac lesions in control mice with myocarditis ( Fig. 2A ). In contrast, healthy hearts from immunized pIV−/− K14 CIITA Tg mice and PBS-immunized MHCII-competent control mice displayed only a scattered pattern of homeostatic MHCII expression ( Fig.  2A ). This MHCII expression appears to be on cardiac professional APCs, mainly macrophages and DCs, which are present in significant numbers in the heart under steady-state conditions [9, 27] . Costaining of MHCII molecules with the endothelial cell marker CD31 reveals that mainly endothelial cells of the interstitial capillary network upregulate MHCII expression in inflamed hearts ( Fig. 2B and C) . The dense cardiac capillary network was previously suggested to play an important role in maintaining intramyocardial microcirculation during contraction and relaxation [28] . In summary, these results confirm that the absence of myocarditis in pIV−/− K14 CIITA Tg mice is in accordance with the lack of MHCII expression on endothelial cells within the heart.
Diseased mice show increased CD4 + T-cell infiltration and IFN-γ expression
We next analyzed hearts from immunized mice for the potential presence of heart-infiltrating CD4 + T cells, which are the key mediators of EAM [2] . We noticed an increase in CD4 + T cells in the hearts of α-MyHC-immunized heterozygous controls as compared to pIV−/− K14 CIITA Tg mice (Fig. 3A) . Moreover, we measured elevated ifn-γ mRNA expression in cardiac explants (Fig. 3B) . IFN-γ is mainly produced by α-MyHC-specific CD4 + T helper type 1 (Th1) cells [29, 30] but non-CD4 + T-cell sources of IFN-γ had been also observed [31] . However, we could not observe a specific increase in IFN-γ + CD8 + T cells in preliminary experiments (data not shown). IFN-γ is the main cytokine-inducing nonhematopoietic MHCII expression [12, 24] . Furthermore, mRNA quantification revealed an increase of mRNAs encoding the proinflammatory chemokines CCL3, CCL4, and CCL5 in the hearts of pIV+/− K14 CIITA Tg mice (Fig. 3C ). These chemokines were previously shown to recruit effector cells during cardiac inflammation [32, 33] .
Neutralization of IFN-γ reduces EAM severity in WT mice
In a model of chronic gut inflammation, we have previously shown that IFN-γ is the main driver of nonhematopoietic MHCII expression by intestinal epithelial cells, and administration of an anti-IFN-γ monoclonal antibody (mAb) reduced inducible nonhematopoietic MHCII expression in vivo [25] . We therefore aimed to examine how systemic neutralization of IFN-γ influences EAM severity in WT mice. To avoid both, interference with initial T-cell polarization and blocking of the late IFN-γ-dependent negative feedback loop confining activated CD4
+ T-cell expansion [34] , neutralizing anti-IFN-γ mAb was administered to WT mice within a window from day 9 until day 19 after primary immunization with α-MyHC peptide and CFA.
As illustrated in Figure 4 , inhibition of IFN-γ let to decreased cardiac MHCII expression (Fig. 4A) and reduced the severity score of EAM (Fig. 4B) in WT mice as compared to isotype-treated mice at day 21 after the first immunization. Our results propose that IFN-γ-induced nonhematopoietic MHCII expression in the heart contributes to EAM, and that the outcome of EAM is improved under anti-IFN-γ treatment.
Discussion
We show here that the absence of inducible MHCII expression protects from EAM induced by immunization with α-MyHC peptide. Heterozygous and WT control mice developed severe myocarditis, and displayed increased cardiac MHCII expression. EAM in the control mice was characterized by an increase in infiltrating CD4 + T cells and in IFN-γ expression, the major factor known to induce nonhematopoietic MHCII expression [12, 24] . Accordingly, we found that neutralization of IFN-γ after initial disease induction reduced cardiac MHCII expression and the histopathological score of EAM in WT mice as compared to isotype-treated controls.
It was previously shown in vivo that IFN-γ is the major cytokine driving the expression of MHCII molecules by nonhematopoietic cells [24] . Moreover, by using an adoptive transfer model of colitis in mice in which IFN-γ is selectively absent on donor and/or recipient mice we had shown that IFN-γ is the exclusive cytokine capable of inducing nonhematopoietic MHCII expression in vivo [25] . Here, we provide evidence that during EAM, MHCII molecules are upregulated mainly on endothelial cells of the cardiac microvasculature, whereas other CD45 − cells, most importantly cardiomyocytes, do not express detectable MHCII molecules. This is consistent with the finding that MHCII expression by cardiac endothelial cells, but not cardiomyocytes, is commonly observed in patients suffering from acute cardiac transplant rejection, myocarditis, and dilated cardiomyopathy [13, 14] . Increased endothelial MHCII expression has also been demonstrated in several other autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus [35] . Based on our results, we propose a model for the contribution of nonhematopoietic MHCII expression during myocarditis ( Fig. 5) : IFN-γ is expressed by primed α-MyHC-specific CD4 + T cells that initially infiltrate cardiac tissue [29, 30] . CD8 + T cells, NK cells, macrophages, and DCs were also suggested to produce IFN-γ in myocarditis [31, 36, 37] . In addition to modulating other immune effector cells, IFN-γ activates pIV of Ciita, leading to the expression of MHCII molecules and presentation of cardiac antigens, such as α-MyHC, by nonhematopoietic cardiac cells. This nonprofessional antigen presentation to infiltrating CD4 + effector T cells is important for the progression of inflammatory dilated cardiomyopathy. IFN-γ is thus proposed to mediate a proinflammatory feedback loop that fosters cardiac autoimmunity. The lack of inducible MHCII in pIV−/− K14 CIITA Tg mice consequently abrogates disease development. Our hypothesis is in ostensible contradiction with reports suggesting that Th1 cells and IFN-γ protect against EAM. Deficiencies in IFN-γ and its receptor were found to lead to exacerbated, progressive, and fatal EAM [6, 22, 38] . IFN-γ-and IFN-γ-induced iNOS were also shown to limit the expansion of α-MyHC-reactive CD4 + T cells in EAM [18, 34, 39] . Finally, T-bet−/− mice, which are impaired in Th1 differentiation, exhibited enhanced disease severity [40] . However, T-bet−/− mice exhibited increased IL-17 production [40] suggesting that exacerbated EAM was a consequence of abnormally increased Th17 responses [41] [42] [43] . It is therefore likely that Th17 cells only become dominant players in EAM in the absence of functional Th1 cells and IFN-γ signalling. Th17 differentiation and/or activity are instead restrained by IFN-γ production in the WT setting. This interpretation is consistent with the observation that mice deficient in IL-17A or its receptor IL-17Rα develop severe EAM comparable to WT mice [7, 44] . However, those mice lack the chronic phase characterized by fibrosis and impairment of cardiac function (termed DCM), which usually occurs in WT mice around days 40 to 70 [7, 44] . Therefore, IL-17A is not essential for the early-stage inflammatory process of acute EAM [43, 44] . Hence in the WT setting, IFN-γ may have an important part in the establishment of acute EAM while IL-17A has an essential role in profibrotic remodeling, chronicity, and progression to DCM. The protective effect of IFN-γ observed in mice deficient in IFN-γ or its receptor [6, 22] is thus likely to be due mainly to the facts that (i) IFN-γ confines activated CD4 + T-cell expansion via nitric oxide [34] , (ii) IFN-γ is involved in regulating CD4 + T-cell activation and apoptosis [31] , and (iii)
IFN-γ suppresses exacerbating Th17 responses [41] [42] [43] , and thus to be unrelated to the IFN-γ-induced MHCII expression addressed in our study. Remarkably, two reports applying distinct models of spontaneous EAM, which are not based on immunization with α-MyHC, proposed that IFN-γ is driving the initial inflammatory phase of EAM [19, 20] . Our finding that neutralization of IFN-γ during the late acute phase of EAM (i.e. when autoagressive CD4 + T cells usually infiltrate cardiac tissues) reduced cardiac MHCII expression and disease severity suggests that once the Th1/Th17 balance is established upon activation of autoreactive CD4 + T cells in lymphoid organs, IFN-γ contributes to cardiac pathology via the upregulation of nonhematopoietic MHCII expression. Interestingly, the strongest EAM phenotype leading to rapid lethality was observed in IFN-γ−/− IL-17A−/− mice, which developed EAM characterized by cardiac eosinophil infiltration and Th2 polarization [43] . This result argues for a greater redundancy among autoinflammatory T-cell subsets in EAM than expected previously and suggests that all Th subsets require precise balancing in order to avoid exacerbated, progressive pathology. Our data are in accordance with the observation that EAM in Lewis rats could be improved by treatment with atorvastatin, Figure 5 . Model on the role of endothelial MHCII expression in EAM. During the heart-specific effector phase, the Th1/Th17 balance is established. IFN-γ expressed by activated Th1 cells in the heart induces the expression of MHCII molecules and hence the presentation of cardiac antigens to infiltrating CD4 + effector T cells. Activated CD4 + effector cells further mediate cardiomyocyte damage by the recruitment of other effector cell populations such as monocytes and neutrophil granulocytes. a drug that was reported to inhibit CIITA expression in the myocardium [15] . Similarly, treatment with adenoviral vectors coding for antisense CIITA RNA during the effector phase of mouse EAM blocked MHCII expression by professional and nonprofessional APCs, and led to a significant reduction in disease severity [45] .
In summary, our findings reveal a previously overlooked role of endothelial and nonhematopoietic MHCII expression in the establishment of autoimmune myocarditis, and our study thus furthers our understanding of the various complex and antithetic roles of IFN-γ during cardiac inflammation. Future research will focus on the specific manipulation of cardiac nonprofessional MHCII expression and antigen presentation to improve the outcome of EAM.
Material and methods
Experimental animals
pIV−/− K14 CIITA Tg mice were described previously [25, 26] and were backcrossed into BALB/c background for more than 12 generations. WT BALB/c mice were purchased from Harlan Laboratories, and were crossed with pIV−/− K14 CIITA Tg to generate heterozygous control mice. Mice were housed in a specific pathogen-free facility at the University of Lausanne and female mice were used between 6 and 12 weeks of age. Experiments were approved by the institutional, cantonal, and federal veterinary authorities.
EAM induction and IFN-γ neutralization
Mice were injected subcutaneously on days 0 and 7 with 100 or 150 μg of α-MyHC peptide (Ac-SLKLMATLFSTYASAD-OH; peptide facility of the Department of Biochemistry, or Ac-RSLKLMATLFSTYASADR-OH; Caslo) emulsified 1:1 with complete Freund's adjuvant (CFA; Sigma-Aldrich). For in vivo IFN-γ neutralization, mice were treated i.p. on days 9, 12, 16, and 19 with 500 μg per injection with an anti-IFN-γ mAb (XMG1.2, self-made), or an isotype control mAb (Y13-259, self-made). Mice were sacrificed for analysis on day 21. In the adoptive transfer model, mice were immunized with α-MyHC peptide as described. Spleens were collected on day 12 and single-cell suspensions were enriched for CD4 + T cells by MACS technology (Miltenyi Biotech). Cells were cultured for 48 h in the presence of 10 μg/ mL α-MyHC peptide before they were intravenously injected into sublethally irradiated WT recipient mice. Mice were sacrificed on day 21 postinjection.
Histopathology and immunohistochemistry
Hearts were removed, fixed in 4% paraformaldehyde, embedded in paraffin, and 4-5 μm cross-sections were stained with hematoxylin and eosin (H&E). Myocarditis severity was evaluated blinded by a clinical pathologist on a semiquantitative scale using grades from 0 to 4 as described previously [10] 
Detection of cardiac troponin T
Blood was collected from the tail vein and serum was purified by centrifugation. Peripheral cTnT levels were measured via the Troponin hs Kit (Roche) on a Modular Analytics E170 machine (Roche) at the Laboratory of Clinical Chemistry (LCC) at the CHUV, Lausanne, Switzerland.
qPCR
Cardiac explants were snap frozen in liquid nitrogen, homogenized by applying the Tissue Lyser II, and RNA was purified with the RNeasy mini Kit (Qiagen). The Superscript II reverse transcriptase Kit (Life Technologies) and random nonamer primers were used for cDNA synthesis. qPCR reactions were performed using a LightCycler 480 SYBR Green I Master Kit on a LightCycler 480 machine (Roche). The following primer sequences were used (from 5 to 3 ): ifn-g forward GGATGCATTCATGAGTATTG, reverse CTTTTCCGCTTCCTGAGG; ccl3 forward CCAAGTCT-TCTCAGCGCCAT, reverse TCCGGCTGTAGGAGAAGCAG; ccl4 forward TCTTGCTCGTGGCTGCCT, reverse GGGAGGGTCA-GAGCCCA; ccl5 forward CCTCACCATCATCCTCACTGC, reverse TCTTCTCTGGGTTGGCACACA; tbp forward CCTTCACCAAT GACTCCTATGAC, reverse CAAGTTTACAGCCAAGATTCAC; b-actin forward GCACAGCTTCTTTGCAGCTCCTTCG, reverse TTTGCACATGCCGGAGCCGTTG. Gene expression for each individual sample was normalized to the housekeeping genes TBP and β-actin via the qBASE PLUS software (Biogazelle).
Flow cytometry
Single-cell suspensions were prepared from digested hearts treated with 0.2 mg/mL Liberase (Roche) for 45 min, followed by enrichment of leukocytes using anti-CD45 magnetic beads (Miltenyi Biotec). Cell suspensions were incubated with antiFcγRII/III (2.4G2). The following antibodies (clones) were used: anti-CD3ε (145-2C11), anti-CD31 (390), anti-CD4 (RM4-5), anti-CD45.2 (104), anti-CD8 (53-6.7), anti-FoxP3 (FJK-16s) (all from eBioscience). Dead cells were excluded by eF506 viability staining (eBioscience). The FoxP3/transcription factor staining buffer set was used for intracellular staining. Samples were analyzed on an LSR II flow cytometer (BD Biosciences), and plotted via the FlowJo software (Tree Star).
Statistical analysis
Differences between groups were determined by the Student's unpaired two-tailed t-test or, when the normality test failed, by the Mann-Whitney Rank Sum test. p-values are indicated when considered statistically significant (*p < 0.05, **p < 0.01, and ***p < 0.001).
